Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of
Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, “Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical
BASKING RIDGE, N.J. , April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 BASKING RIDGE, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service ( NHS ) has exercised its option to
BASKING RIDGE, N.J. , April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate
Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults BASKING RIDGE, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced
BASKING RIDGE, N.J. , March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a
John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience BASKING RIDGE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm ET BASKING RIDGE, N.J. , March 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter 2019
Conference Call to be Held at 4:45pm Eastern Time BASKING RIDGE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019